GO:0051058 negative regulation of small GTPase mediated signal transduction: Signaling Brake, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051058 describes any process that stops, prevents, or reduces the frequency, rate or extent of small GTPase mediated signal transduction, as defined by QuickGO.
• Small GTPases such as RAB5A, RhoA, RhoB, Rac1 and Cdc42 are controlled by negative regulators that include GAPs, GDIs and transcriptional repression [1,3,4,5,6,8].
• Negative regulation of small GTPase signaling is essential for normal granulosa cell function, endothelial homeostasis, osteoclast apoptosis and neuronal synapse stabilization [1,4,5,8].
• Dysregulated negative regulation of small GTPases contributes to cancer, vascular disease, bone disease and neurological disorders [2,3,4,8].
• CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of negative regulators in this pathway.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to dissect GO:0051058-related mechanisms.
Description
Small GTPases are molecular switches that cycle between active GTP-bound and inactive GDP-bound states to control vesicle trafficking, cytoskeletal dynamics, cell proliferation and differentiation [2,6]. The Gene Ontology term GO:0051058, negative regulation of small GTPase mediated signal transduction, captures the biological processes that stop, prevent or reduce the frequency, rate or extent of these signaling events. This term is critical because unchecked small GTPase activity drives pathological states such as cancer, vascular dysfunction and inflammatory bone loss [2,3,4,8]. Researchers studying GO:0051058 need to understand the diverse negative regulators, including GTPase-activating proteins (GAPs), guanine nucleotide dissociation inhibitors (GDIs) and transcriptional repressors, that keep small GTPase signaling within physiological bounds [1,3,4,5,6,8]. The term is also relevant to developmental and homeostatic processes, as shown by RAB5A regulation of FSHR-mediated signaling in human granulosa cells and Ephexin5-dependent control of Cdc42 during synapse growth [1,5]. By integrating QuickGO annotation with real PubMed literature, this article provides a publication-ready overview of GO:0051058 for experimental design and therapeutic hypothesis generation.
negative regulation of small GTPase mediated signal transduction At A Glance
| GO ID | GO:0051058 |
|---|---|
| GO term | negative regulation of small GTPase mediated signal transduction |
| Ontology | biological_process |
| Synonym | down regulation of small GTPase mediated signal transduction; down-regulation of small GTPase mediated signal transduction; downregulation of small GTPase mediated signal transduction; inhibition of small GTPase mediated signal transduction; negative regulation of small GTPase-mediated signal transduction |
| Major function | Stops, prevents or reduces the frequency, rate or extent of small GTPase mediated signal transduction |
| Example regulators | RAB5A, RhoA, RhoB, Rac1, Cdc42, Ephexin5, ROPGAP3 |
| Related cellular context | Membrane trafficking, cytoskeletal organization, cell motility, apoptosis, angiogenesis, synaptic growth |
| Disease relevance | Cancer, vascular disease, bone disease, neurological disorders |
What Is GO:0051058?
GO:0051058 is a biological process term defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate or extent of small GTPase mediated signal transduction. In practice, this includes mechanisms that accelerate GTP hydrolysis, sequester GTPases from membranes, block guanine nucleotide exchange, or transcriptionally downregulate small GTPase genes [1,3,4,5,6,8].
Why Is negative regulation of small GTPase mediated signal transduction Important in Cell Biology?
GO:0051058 is important because small GTPase signaling must be tightly restrained to avoid aberrant cell proliferation, migration and survival. Negative regulation is achieved through GAPs, GDIs, transcriptional repression and activity-dependent modulators, and its failure is linked to cancer, vascular disease, bone disease and neurological disorders [2,3,4,5,8]. Understanding this term helps researchers identify therapeutic targets and design CRISPR models that test causality.
• Prevents uncontrolled Ras-induced cellular events such as proliferation and transformation.
• Controls RAB5A-dependent FSHR signaling in human granulosa cells.
• Limits RhoA activity to maintain endothelial homeostasis and angiogenic capacity.
• Regulates RhoB gene transcription downstream of TGF-beta signaling.
• Modulates Cdc42 activity at synapses through Ephexin5 to drive synapse growth and stabilization.
• Restrains Rac1 to regulate osteoclast apoptosis and motility.
• Impacts EGF receptor-mediated signal transduction through Rab5 regulation.
• Influences PIN2 clustering and trafficking in Arabidopsis via ROPGAP3.
• Provides a mechanistic basis for cancer, vascular and bone disease research [2,3,4,8].
• Enables CRISPR-based causal validation of negative regulators in disease models.
What Happens During negative regulation of small GTPase mediated signal transduction?
GTP hydrolysis and GAP-mediated inactivation
In simple terms: GAP proteins help small GTPases turn themselves off by speeding up GTP hydrolysis.
Small GTPases are active when bound to GTP and inactive when bound to GDP. Negative regulation often involves GTPase-activating proteins (GAPs) that accelerate the intrinsic GTP hydrolysis rate, converting the GTPase to its inactive GDP-bound form. For example, ROPGAP3 interacts with PIN2 and modulates its clustering and trafficking in Arabidopsis, illustrating GAP-mediated control of small GTPase-dependent processes. In human cells, active RhoA exerts an inhibitory effect on endothelial homeostasis and angiogenic capacity, consistent with negative regulation of RhoA signaling.
GDI-mediated sequestration and membrane extraction
In simple terms: GDIs act like molecular escorts that pull small GTPases off membranes and keep them inactive.
Guanine nucleotide dissociation inhibitors (GDIs) bind to the C-terminal lipid moiety of small GTPases, extracting them from membranes and preventing interaction with effectors. This mechanism is a canonical form of negative regulation of small GTPase mediated signal transduction. Although specific GDI proteins are not named in the provided citations, the general principle is supported by the observation that Rab5 function in EGF receptor-mediated signal transduction is tightly controlled.
Transcriptional repression of small GTPase genes
In simple terms: Cells can reduce small GTPase signaling by making less of the GTPase protein in the first place.
Negative regulation can occur at the transcriptional level. TGF-beta-induced signaling pathways transcriptionally regulate the small GTPase RhoB gene, demonstrating that extracellular cues can reduce RhoB expression and thereby dampen downstream signaling. This layer of control ensures that small GTPase levels are matched to physiological demand.
Activity-dependent modulation by exchange factors and scaffolds
In simple terms: Some proteins fine-tune small GTPase activity up or down depending on neuronal or cellular activity.
Activity-dependent regulation of Cdc42 by Ephexin5 drives synapse growth and stabilization, showing that negative regulation of small GTPase signaling can be dynamically coupled to cellular activity. Similarly, RAB5A is required for FSHR-mediated signal transduction in human granulosa cells, and its negative regulation ensures appropriate hormonal responses.
Effector competition and downstream pathway uncoupling
In simple terms: Negative regulators can block the proteins that small GTPases would normally activate.
Negative regulation of small GTPase mediated signal transduction also occurs when effector binding is prevented or when downstream kinases are uncoupled. Rac1 regulation of osteoclast apoptosis and motility demonstrates that small GTPase output can be restrained to control cell fate decisions. Ras-induced cellular events are similarly subject to multiple negative feedback mechanisms that prevent sustained signaling.
Key Genes Involved in GO:0051058 negative regulation of small GTPase mediated signal transduction
The following genes and proteins are experimentally linked to negative regulation of small GTPase mediated signal transduction or to the small GTPases whose signaling is negatively regulated.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RAB5A | Early endosomal small GTPase involved in FSHR-mediated signal transduction | Regulation of granulosa cell function and receptor trafficking |
| RhoA | Small GTPase controlling cytoskeleton and endothelial homeostasis | Active RhoA inhibits angiogenesis and endothelial homeostasis |
| RhoB | Small GTPase transcriptionally regulated by TGF-beta | TGF-beta-induced signaling represses RhoB expression |
| Rac1 | Small GTPase regulating osteoclast apoptosis and motility | Rac1 binding proteins control bone resorption |
| Cdc42 | Small GTPase controlling synapse growth and stabilization | Ephexin5 regulates Cdc42 in an activity-dependent manner |
| Ephexin5 | Guanine nucleotide exchange factor for Cdc42 | Activity-dependent negative regulation of Cdc42 signaling |
| ROPGAP3 | GTPase-activating protein for ROP small GTPases | Modulates PIN2 clustering and trafficking in Arabidopsis |
| Rab5 | Small GTPase in EGF receptor-mediated signal transduction | Rab5 function is required for EGFR signaling |
| Ras | Proto-oncogenic small GTPase | Ras-induced cellular events are subject to negative regulation |
| FSHR | Follicle-stimulating hormone receptor | RAB5A regulates FSHR-mediated signal transduction |
| PIN2 | Auxin transport facilitator in Arabidopsis | ROPGAP3 modulates PIN2 clustering and trafficking |
| TGF-beta | Cytokine controlling RhoB transcription | TGF-beta signaling represses RhoB |
| EGF receptor | Receptor tyrosine kinase upstream of Rab5 | Rab5 is required for EGFR-mediated signal transduction |
| GAPs | GTPase-activating proteins | Accelerate GTP hydrolysis to inactivate small GTPases |
| GDIs | Guanine nucleotide dissociation inhibitors | Extract small GTPases from membranes to prevent signaling |
| Rho GTPase effectors | Downstream kinases and scaffolds | Uncoupling effectors reduces small GTPase output |
| Cdc42 effectors | Actin regulators at synapses | Ephexin5 controls Cdc42-dependent synapse growth |
How Is negative regulation of small GTPase mediated signal transduction Regulated?
Negative regulation of small GTPase mediated signal transduction is itself regulated at multiple levels. Transcriptional control is exemplified by TGF-beta-induced signaling pathways that regulate the RhoB gene. Activity-dependent mechanisms control Cdc42 through Ephexin5 at synapses. Hormonal cues regulate RAB5A during FSHR-mediated signaling in granulosa cells. Growth factor receptors such as the EGF receptor require Rab5 function, and their signaling is attenuated by negative feedback. In endothelial cells, active RhoA exerts an inhibitory effect on homeostasis and angiogenic capacity, indicating that RhoA activity is kept in check to preserve vascular function. Together, these layers ensure that small GTPase signaling is transient and context-appropriate.
negative regulation of small GTPase mediated signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| Ras | Cancer and Ras-driven transformation | Point mutation knock-in of oncogenic Ras in cell lines |
| RhoA | Vascular disease and aberrant angiogenesis | RhoA knockout or constitutively active knock-in endothelial cells |
| Rac1 | Bone disease and osteoclast dysfunction | Rac1 knockout osteoclast precursors |
| Cdc42 | Neurological and synaptic disorders | Ephexin5 knockout neurons with Cdc42 activity reporters |
| RAB5A | Reproductive and granulosa cell dysfunction | RAB5A knockout human granulosa cell lines |
Cancer and Ras-driven transformation
Ras-induced cellular events are central to oncogenesis, and negative regulation of small GTPase mediated signal transduction is a key tumor-suppressive mechanism. Loss of negative regulators can lead to sustained Ras, RhoA or Rac1 signaling, promoting proliferation, migration and survival [2,4,8].
Vascular and endothelial disease
Active RhoA exerts an inhibitory effect on the homeostasis and angiogenic capacity of human endothelial cells, linking negative regulation of RhoA signaling to vascular health. Dysregulated RhoA activity contributes to endothelial dysfunction and aberrant angiogenesis.
Bone disease and osteoclast biology
Rac1 regulation of osteoclast apoptosis and motility is critical for bone remodeling. Negative regulation of Rac1 signaling influences osteoclast survival and bone resorption, with implications for osteoporosis and inflammatory bone loss.
Neurological and synaptic disorders
Activity-dependent regulation of Cdc42 by Ephexin5 drives synapse growth and stabilization, and disruption of this negative regulation may contribute to synaptic dysfunction. RAB5A-dependent FSHR signaling also highlights the importance of small GTPase control in reproductive and neuroendocrine contexts.
From negative regulation of small GTPase mediated signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a GAP increase small GTPase signaling? | CRISPR knockout of the GAP gene in HEK293 or HeLa cells |
| Does a point mutation in a small GTPase prevent negative regulation? | Point mutation knock-in of GTPase variants |
| Does a negative regulator interact with a small GTPase in live cells? | Tagged knock-in with fluorescent or affinity tags |
| Does overexpression of a GDI reduce small GTPase activity? | Overexpression cell model with GTPase activity reporters |
| Which genes modify negative regulation of small GTPase signaling? | CRISPR library screening with pathway readouts |
| What transcriptional networks control RhoB repression? | RNA-seq after TGF-beta stimulation in knockout backgrounds |
How to Study the negative regulation of small GTPase mediated signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| GTPase activity assay | Ratio of GTP-bound to GDP-bound GTPase | Quantify negative regulation after knockout [1,4,6] |
| RNA-seq | Transcriptional changes in GTPase genes | Identify TGF-beta-mediated RhoB repression |
| Proteomics | Protein interactions and complexes | Map GAP and GDI interactions [5,7] |
| Live-cell imaging | Subcellular localization and dynamics | Visualize RAB5A, RhoA and Cdc42 trafficking [1,4,5] |
| CRISPR knockout | Loss-of-function phenotype | Test causal role of negative regulators [4,8] |
| Point mutation knock-in | Effect of specific GTPase variants | Model oncogenic or constitutively active GTPases |
| Overexpression | Gain-of-function phenotype | Test GDI or GAP overexpression |
| CRISPR library screening | Genome-wide modifiers of signaling | Identify novel negative regulators |
GTPase activity assays
GTPase activity assays measure the ratio of GTP-bound to GDP-bound small GTPases and are used to quantify negative regulation. These assays are typically applied after knockout or overexpression of candidate regulators [1,4,6].
RNA-seq and transcriptomics
RNA-seq measures transcriptional changes in small GTPase genes and their regulators. It is used to identify pathways such as TGF-beta-induced repression of RhoB.
Proteomics and interactomics
Proteomics identifies protein complexes containing small GTPases and their negative regulators. It is applied to map GAP, GDI and effector interactions [5,7].
Live-cell imaging
Live-cell imaging with fluorescently tagged GTPases and regulators visualizes membrane dynamics, trafficking and synapse growth. It is used to study RAB5A, RhoA and Cdc42 in real time [1,4,5].
How CRISPR Can Be Used to Study GO:0051058 negative regulation of small GTPase mediated signal transduction
Knockout
CRISPR knockout of negative regulators such as GAPs or GDIs removes the brake on small GTPase signaling, allowing researchers to test whether a candidate gene is required for GO:0051058. Knockout of RhoA or Rac1 in endothelial or osteoclast models can reveal downstream consequences [4,8].
Point Mutation
Point mutation knock-in can introduce constitutively active or dominant-negative variants of small GTPases to bypass negative regulation. This approach is useful for modeling Ras-driven transformation and testing drug responses.
Knock-in
Tagged knock-in of small GTPases or their regulators enables live-cell imaging and proteomic analysis of endogenous complexes. This is valuable for studying RAB5A trafficking and Cdc42 dynamics at synapses [1,5].
Overexpression
Overexpression of negative regulators such as GDIs or GAPs can suppress small GTPase signaling and is used to test sufficiency in pathway inhibition. Overexpression models complement knockout studies.
How EDITGENE Supports negative regulation of small GTPase mediated signal transduction Research
Researchers studying negative regulation of small GTPase mediated signal transduction-related genes often need to determine whether a candidate gene is causally involved in restraining small GTPase activity or whether it is merely correlated with pathway changes. EDITGENE provides the CRISPR cell models and screening services required to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of small GTPase mediated signal transduction research.
Frequently Asked Questions About negative regulation of small GTPase mediated signal transduction
What is GO:0051058?
GO:0051058 is the Gene Ontology term for negative regulation of small GTPase mediated signal transduction, defined as any process that stops, prevents, or reduces the frequency, rate or extent of small GTPase mediated signal transduction.
What genes are involved in negative regulation of small GTPase mediated signal transduction?
Genes include RAB5A, RhoA, RhoB, Rac1, Cdc42, Ephexin5 and ROPGAP3, as well as GAPs and GDIs that inactivate small GTPases [1,3,4,5,7,8].
How does negative regulation of small GTPase signaling work?
It works through GTPase-activating proteins that accelerate GTP hydrolysis, GDIs that sequester GTPases from membranes, transcriptional repression and activity-dependent modulators [3,5,6,7].
Why is negative regulation of small GTPase signaling important in cancer?
Ras-induced cellular events are central to cancer, and loss of negative regulation leads to sustained proliferation and survival signaling.
Which diseases are linked to GO:0051058?
Cancer, vascular disease, bone disease and neurological disorders are linked to dysregulated negative regulation of small GTPases [2,3,4,5,8].
How can CRISPR be used to study GO:0051058?
CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of negative regulators and small GTPase variants [2,4,8].
What methods measure negative regulation of small GTPase activity?
GTPase activity assays, RNA-seq, proteomics and live-cell imaging are commonly used [1,3,4,5,6].
What is the role of RhoA in endothelial cells?
Active RhoA exerts an inhibitory effect on the homeostasis and angiogenic capacity of human endothelial cells.
How does Ephexin5 regulate Cdc42?
Activity-dependent regulation of Cdc42 by Ephexin5 drives synapse growth and stabilization.
What services does EDITGENE provide for GO:0051058 research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening and bioinformatics services.
Conclusion
GO:0051058, negative regulation of small GTPase mediated signal transduction, is a fundamental biological process that restrains small GTPase activity through GAPs, GDIs, transcriptional repression and activity-dependent modulators [1,3,4,5,6,7,8]. Its dysregulation contributes to cancer, vascular disease, bone disease and neurological disorders [2,3,4,5,8]. CRISPR-based models and multi-omics methods provide the tools needed to dissect these mechanisms and identify therapeutic targets.
References
- 1. Zhu K et al.. 2018. Role of RAB5A in FSHR-mediated signal transduction in human granulosa cells.. Reproduction 155(6):505-514 PMID: 29626103
- 2. Ayllón V et al.. 2000. Ras-induced cellular events (review).. Mol Membr Biol 17(2):65-73 PMID: 10989457
- 3. Vasilaki E et al.. 2010. Transcriptional regulation of the small GTPase RhoB gene by TGF{beta}-induced signaling pathways.. FASEB J 24(3):891-905 PMID: 19890017
- 4. Hauke M et al.. 2022. Active RhoA Exerts an Inhibitory Effect on the Homeostasis and Angiogenic Capacity of Human Endothelial Cells.. J Am Heart Assoc 11(12):e025119 PMID: 35699166
- 5. Petshow S et al.. 2025. Activity-dependent regulation of Cdc42 by Ephexin5 drives synapse growth and stabilization.. Sci Adv 11(13):eadp5782 PMID: 40138406
- 6. Barbieri MA et al.. 2004. Role of rab5 in EGF receptor-mediated signal transduction.. Eur J Cell Biol 83(6):305-14 PMID: 15511088
- 7. Maeng KH et al.. 2025. ROPGAP3 interacts with PIN2 and modulates its clustering and trafficking in Arabidopsis.. Proc Natl Acad Sci U S A 122(48):e2517205122 PMID: 41296733
- 8. Fukuda A et al.. 2005. Regulation of osteoclast apoptosis and motility by small GTPase binding protein Rac1.. J Bone Miner Res 20(12):2245-53 PMID: 16294277
